Business Description

Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 0.16
Equity-to-Asset 0.57
Debt-to-Equity 0.46
Debt-to-EBITDA 3.3
Interest Coverage 7.43
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.45
Distress
Grey
Safe
Beneish M-Score -2.34
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.1
Quick Ratio 1.32
Cash Ratio 0.33
Days Inventory 321.95
Days Sales Outstanding 79.03
Days Payable 65.56

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 1.7
Shareholder Yield % -0.87

Financials (Next Earnings Date:2024-07-25 Est.)

XSGO:BIIB's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Biogen Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 9,663.1
EPS (TTM) ($) 8.01
Beta 0
Volatility % 0
14-Day RSI 0
14-Day ATR ($) 0
20-Day SMA ($) 245
12-1 Month Momentum % 0
52-Week Range ($) 245 - 245
Shares Outstanding (Mil) 145.6

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biogen Inc Filings

Filing Date Document Date Form
No Filing Data

Biogen Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Biogen Inc Frequently Asked Questions

What is Biogen Inc(XSGO:BIIB)'s stock price today?
The current price of XSGO:BIIB is $245.00. The 52 week high of XSGO:BIIB is $245.00 and 52 week low is $245.00.
When is next earnings date of Biogen Inc(XSGO:BIIB)?
The next earnings date of Biogen Inc(XSGO:BIIB) is 2024-07-25 Est..
Does Biogen Inc(XSGO:BIIB) pay dividends? If so, how much?
Biogen Inc(XSGO:BIIB) does not pay dividend.

Press Release

Subject Date
No Press Release